← 返回

趋化因子(C-C 基序)配体 7 在肿瘤和炎症性疾病中的双重作用

英文原题:The dual roles of chemokine (C-C motif) ligand 7 in tumors and inflammatory diseases.

查看英文原题

The dual roles of chemokine (C-C motif) ligand 7 in tumors and inflammatory diseases.

PubMed 2026/01/29(内容时间) PeerJ Q2 · IF 2.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

趋化因子被认为是肿瘤生长和炎症的主要贡献者。它们直接参与癌症进展,并因炎症反应和免疫细胞浸润而加速肿瘤微环境(TME)重塑。C-C基序趋化因子配体7(CCL7)广泛表达于多种细胞类型。在肿瘤中,CCL7通过塑造TME并促进细胞侵袭和转移来促进进展。它还通过招募T细胞和NK细胞等免疫细胞来增强抗肿瘤免疫反应。

此外,新出现的证据表明,CCL7的过表达与炎症性疾病相关。CCL7主要吸引巨噬细胞和单核细胞,从而调节炎症反应、驱动纤维化进展并维持全身稳态。

然而,这些过程的确切机制仍不清楚,且缺乏系统性研究。本综述系统整合了CCL7在肿瘤中的双重作用(既促肿瘤又抗肿瘤)及其在炎症(既促炎又抗炎)、纤维化和肥胖中的阶段特异性功能,填补了以往研究零散化的空白。它还关联了多种疾病中的共同调控机制,并提出CCL7/CCR拮抗剂和联合免疫治疗等具体策略,从而为相关疾病的探索和治疗提供新的治疗策略,旨在为全球人类健康维护作出贡献。

展开英文摘要原文

Chemokines are regarded as major contributors to tumor growth and inflammation. They participate in cancer progression directly and accelerate tumor microenvironment (TME) remodeling because of the inflammatory response and immune cell infiltration. C-C motif chemokine ligand 7 (CCL7) is widely expressed across various cell types. In tumors, CCL7 facilitates progression by shaping the TME and promoting cell invasion and metastasis. It also enhances anti-tumor immune responses by recruiting immune cells such as T cells and NK cells.

Moreover, emerging evidence indicates that the overexpression of CCL7 is associated with inflammatory diseases. CCL7 predominantly attracts macrophages and monocytes, thereby modulating inflammatory responses, driving fibrosis progression, and maintaining systemic homeostasis.

However, the exact mechanisms underlying these processes remain unclear and lack systematic investigation. This review systematically integrates CCL7's dual roles in tumors (both pro-tumor and anti-tumor) and its stage-specific functions across inflammation (both pro-inflammatory and anti-inflammatory), fibrosis, and obesity, filling gaps in fragmented prior research.

It also links the common regulatory mechanisms across multiple diseases, and puts forward specific strategies such as CCL7/CCR antagonists and combined immunotherapy, thereby providing new therapeutic strategies for the exploration and treatment of related diseases, aiming to contribute to the maintenance of human health globally.

论文信息

作者
Qian D、Mo Y、Chen J、Guan W、Yan L、Zhou Q
单位
Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou, China.China
文献类型
综述
期刊
PeerJ2026
原文标识
PubMed 41630845 · DOI 10.7717/peerj.20685